Normec partners with MIAS Pharma

Amsterdam, Dublin, 12 August 2024 – Normec, a leading provider of Testing, Inspection, Certification, and Compliance (TICC) services, is delighted to announce its acquisition of MIAS Pharma, a distinguished provider of pharmaceutical consulting and Qualified Person (QP) services based in Ireland and the UK.

MIAS Pharma specialises in Clinical and Commercial QP services, along with holding Manufacturer’s/Importation Authorisations (MIAs), which enable the company to manage market importation and batch certification processes for medicinal products. Their expertise and services are highly valued in the pharmaceutical industry for ensuring regulatory compliance and maintaining high standards of quality.

The integration of MIAS Pharma into Normec not only broadens Normec’s healthcare service offerings but also reinforces its commitment to delivering comprehensive solutions to life sciences customers. The current leadership of MIAS Pharma, including owner Ann McGee and CEO Pierre Baviera will remain actively involved, ensuring a smooth transition and continued operational excellence.

Joep Bruins, founder and CEO of Normec, expressed his enthusiasm: “We are thrilled to welcome MIAS Pharma to Normec. This acquisition aligns perfectly with our strategic goals to enhance our service offerings and geographic presence in the life sciences sector. MIAS Pharma’s reputation for excellence and their specialized services will be a tremendous asset to Normec.”

Ann McGee and Pierre Baviera commented: “MIAS Pharma is delighted to announce its integration with the Normec Group, a move that will significantly enhance our capabilities and expand our service offerings. This collaboration promises to drive innovation and ensure the highest quality standards for our clients and partners.”

Normec were advised on the transaction by KPMG (financial and tax) and McCann FitzGerald LLP (legal). MIAS Pharma were advised by Addleshaw Goddard LLP.

Contact info

Frederik Bernoski, General Counsel, frederik.bernoski@normecgroup.com

Mike de Groot, Chief Investment Officer, mike.de.groot@normecgroup.com